WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "481f7669-92c0-4318-acea-d0f36c1fb271"}, "_deposit": {"created_by": 3, "id": "26800", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "26800"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00026800", "sets": ["1763"]}, "author_link": ["491", "20454", "45274", "21459", "45276", "45278", "45279", "45275", "329", "45277", "97"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-12-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "328", "bibliographicPageStart": "323", "bibliographicVolumeNumber": "336", "bibliographic_titles": [{"bibliographic_title": "Biomedical research"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective.", "subitem_description_type": "Abstract"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Biomedical Research Foundation"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.2220/biomedres.33.323", "subitem_relation_type_select": "DOI"}}]}, "item_4_relation_28": {"attribute_name": "関連URI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://japanlinkcenter.org/DN/JST.JSTAGE/biomedres/33.323", "subitem_relation_type_select": "URI"}}, {"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.jstage.jst.go.jp/article/biomedres/33/6/33_323/_article", "subitem_relation_type_select": "URI"}}]}, "item_4_rights_23": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright © 2012 Biomedical Research Press"}]}, "item_4_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA12050384", "subitem_source_identifier_type": "NCID"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1880-313X", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kadono, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "329", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10397218", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=10397218"}, {"nameIdentifier": "10397218", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000010397218"}]}, {"creatorNames": [{"creatorName": "Miwa, Sotaro"}], "nameIdentifiers": [{"nameIdentifier": "491", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80507070", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000080507070"}]}, {"creatorNames": [{"creatorName": "Shima, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "45274", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Konaka, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "21459", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40334768", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40334768"}, {"nameIdentifier": "40334768", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000040334768"}]}, {"creatorNames": [{"creatorName": "Mizokami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "97", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=50248580"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=50248580"}, {"nameIdentifier": "50248580", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000050248580"}]}, {"creatorNames": [{"creatorName": "Yotsuyanagi, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "45275", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirata, Akio"}], "nameIdentifiers": [{"nameIdentifier": "45276", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takase, Yasukazu"}], "nameIdentifiers": [{"nameIdentifier": "45277", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugata, Toshiaki"}], "nameIdentifiers": [{"nameIdentifier": "45278", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimamura, Masayoshi"}], "nameIdentifiers": [{"nameIdentifier": "45279", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Namiki, Mikio"}], "nameIdentifiers": [{"nameIdentifier": "20454", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "70155985", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=70155985"}, {"nameIdentifier": "70155985", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000070155985"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-KADONO-Y-323.pdf", "filesize": [{"value": "307.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 307000.0, "url": {"label": "ME-PR-KADONO-Y-323.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/26800/files/ME-PR-KADONO-Y-323.pdf"}, "version_id": "ce326f5a-4174-4a8d-88f9-0a64a3fdb627"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma"}]}, "item_type_id": "4", "owner": "3", "path": ["1763"], "permalink_uri": "http://hdl.handle.net/2297/34162", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-05"}, "publish_date": "2017-10-05", "publish_status": "0", "recid": "26800", "relation": {}, "relation_version_is_last": true, "title": ["The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma"], "weko_shared_id": -1}
The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma
http://hdl.handle.net/2297/34162
http://hdl.handle.net/2297/3416251f9eb8b-d29d-4f0e-bf1b-71f7b43a975f
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-KADONO-Y-323.pdf (307.0 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-05 | |||||
タイトル | ||||||
タイトル | The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kadono, Yoshifumi
× Kadono, Yoshifumi× Miwa, Sotaro× Shima, Takashi× Konaka, Hiroyuki× Mizokami, Atsushi× Yotsuyanagi, Satoshi× Hirata, Akio× Takase, Yasukazu× Sugata, Toshiaki× Shimamura, Masayoshi× Namiki, Mikio |
|||||
書誌情報 |
Biomedical research 巻 336, 号 6, p. 323-328, 発行日 2012-12-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1880-313X | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA12050384 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.2220/biomedres.33.323 | |||||
出版者 | ||||||
出版者 | Biomedical Research Foundation | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective. | |||||
権利 | ||||||
権利情報 | Copyright © 2012 Biomedical Research Press | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://japanlinkcenter.org/DN/JST.JSTAGE/biomedres/33.323 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.jstage.jst.go.jp/article/biomedres/33/6/33_323/_article |